CSET's Dr. Caroline Schuerger, Dr. Steph Batalis, and Vikram Venkatram submitted this comment with recommendations for the National Biotechnology and Biomanufacturing Initiative.

CSET's Anna Puglisi and Andrew Imbrie discuss actions democracies can take to shape the development of biotechnology.

CSET hosted a discussion with Dr. Amesh Adalja, Senior Scholar at the Johns Hopkins University Center for Health Security, on the importance of understanding the breadth and depth of global biological activity in preparing for future pandemics.

Biosafety Level-3 laboratories (BSL-3) are an essential part of research infrastructure and are used to develop vaccines and therapies. The research conducted in them provides insights into host-pathogen interactions that may help prevent future pandemics. However, these facilities also potentially pose a risk to society through lab accidents or misuse. Despite their importance, there is no comprehensive list of BSL-3 facilities, or the institutions in which they are housed. By systematically assessing PubMed articles published in English from 2006-2021, this paper maps institutions that host BSL-3 labs by their locations, augmenting current knowledge of where high-containment research is conducted globally.

China is banking on applying AI to biotechnology research in order to transform itself into a “biotech superpower.” In pursuit of that goal, it has emphasized bringing together different aspects of the development cycle to foster multidisciplinary research. This data brief examines the emerging trend of co-location of AI and biotechnology researchers and explores the potential impact it will have on this growing field.

CSET Research Fellow Caroline Schuerger testified before the Bipartisan Commission on Biodefense hearing on "The Biological Threat Expanse" Current and Future Challenges to National Biodefense." She discussed threats to the bioeconomy and steps the U.S. and its allies can take to harness biotechnology's capabilities and raise awareness of risky research.